Notice

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at USA.gov.

September 2017 DAIT Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements .

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Cooperative Centers of Human Immunology

For the published request for applications, see the December 4, 2017 Guide announcement, Cooperative Centers on Human Immunology (U19 Clinical Trial Optional).

Maintaining Immunity After Immunization

For the published request for applications, see the October 20, 2017 Guide announcement, Maintaining Immunity After Immunization (U01, Clinical Trial Optional).

Vaccine Adjuvant Discovery Program

Broad Agency Announcement—proposed FY 2019 initiative

Contact: George Ralis

Objective: Discovery of novel vaccine adjuvant candidates (products) and novel insights into basic immune mechanisms related to adjuvant function (scientific advances).

Description: The objective of the program is the discovery, optimization, and early-stage development of novel vaccine adjuvant candidates, using high-throughput screening of compound libraries, structure-activity-studies with the goal of improving lead compounds through medicinal chemistry, mechanism-of-action studies with the ultimate goal of gaining insights into immune mechanisms of adjuvanticity, and in vivo efficacy studies using well-defined animal models of infectious diseases.

Immune Mechanisms of Protection Against Mycobacterium tuberculosis Consortium (IMPAc-TB)

Broad Agency Announcement—proposed FY 2019 initiative

Contact: Albert Nguyen

Objective: To support coordinated, multidisciplinary research teams that will intensively study systemic and tissue-specific human immune responses generated by vaccination against Mycobacterium tuberculosis (Mtb) and/or during natural infection, together with comparative, mechanistic studies in nonhuman primate (NHP) and small animal models. This program will also support studies to determine the impact of HIV/SIV infection on relevant immune responses to natural Mtb infection or TB vaccines. The ultimate goal of this program is to accelerate elucidation of immune mechanisms that can be used to advance novel TB vaccine strategies while also increasing the predictive value of animal models.

Description: There is a significant need to improve understanding of the quality, quantity, timing, and location of immune responses required to protect humans against TB. The primary goal of the IMPAc-TB program is to identify and characterize immune responses required to protect a host from initial Mtb infection, establishing latent infection, or progressing to active TB disease. Each IMPAc-TB team must examine at least two of these three Mtb /TB stages and conduct iterative immunologic studies using small animal models, NHP, and human studies.

It is anticipated that the proposed research will require close collaboration between investigators to coordinate research between human and animal studies, facilitate collecting and distributing specimens and other novel research resources amongst Consortium members, and rapidly and synergistically pursue new discoveries. Funded investigators will also be encouraged to share both positive and negative results to help guide research and development activities within the Consortium(a) and across the broader scientific community.

In addition to required research foci, each Consortium will be required to include a well-defined collaborative leadership structure with defined processes for strategic planning and resource allocation and a dedicated project manager. Each Consortium shall propose an integrated scientific scope and be encouraged to incorporate innovative strategies to accomplish an individual program’s goals.

Furthermore, it is envisioned that each will incorporate state-of-the art immunologic assays to study functional immunity and will collaborate with existing NIAID-supported and other large TB programs, which may include leveraging ongoing TB vaccine trials for sample collection and analyses.

Content last reviewed on October 23, 2017